Journal article
Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice
T Spelman, C Meyniel, JI Rojas, A Lugaresi, G Izquierdo, F Grand’Maison, C Boz, R Alroughani, E Havrdova, D Horakova, G Iuliano, P Duquette, M Terzi, P Grammond, R Hupperts, J Lechner-Scott, C Oreja-Guevara, E Pucci, F Verheul, M Fiol Show all
Multiple Sclerosis | SAGE PUBLICATIONS LTD | Published : 2017
Abstract
Background: Characteristics at clinically isolated syndrome (CIS) examination assist in identification of patient at highest risk of early second attack and could benefit the most from early disease-modifying drugs (DMDs). Objective: To examine determinants of second attack and validate a prognostic nomogram for individualised risk assessment of clinical conversion. Methods: Patients with CIS were prospectively followed up in the MSBase Incident Study. Predictors of clinical conversion were analysed using Cox proportional hazards regression. Prognostic nomograms were derived to calculate conversion probability and validated using concordance indices. Results: A total of 3296 patients from 50..
View full abstractGrants
Awarded by Canadian Institutes of Health Research
Funding Acknowledgements
The author(s) disclosed receipt of the following financial support for the research, authorship and/or publication of this article: The work was supported by the NHMRC Career Development Award (Clinical) to HB (ID628856), NHMRC Project Grant (1032484), NHMRC Centre of Research Excellence (grant ID 1001216) and the MSBase Foundation. The MSBasis study was specifically supported by Merck Serono, between 2004 and 2009. The MSBase Foundation is a not-for-profit organisation that receives support from Merck Serono, Biogen Idec, Novartis Pharma, Bayer-Schering, Sanofi-Aventis and BioCSL. Claire Meyniel was supported by the Journees de Neurologie de Langue Francaise.